Financial Constraints to Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Dr Wainberg and Dr Gerson review why providers are using combination therapies and the eventual goal of investigators to hit specific targeted cells.
Dr. Gary Palmer discusses the different profile of tumors and how to make findings as general as possible to better treat the patient.